In the last trading session, 0.14 million shares of the Climb Bio Inc (NASDAQ:CLYM) were traded, and its beta was -0.25. Most recently the company’s share price was $1.95, and it changed around -$0.06 or -2.99% from the last close, which brings the market valuation of the company to $131.24M. CLYM currently trades at a discount to its 52-week high of $11.55, offering almost -492.31% off that amount. The share price’s 52-week low was $1.73, which indicates that the current value has risen by an impressive 11.28% since then. We note from Climb Bio Inc’s average daily trading volume that its 10-day average is 0.72 million shares, with the 3-month average coming to 394.68K.
Climb Bio Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended CLYM as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight.
Climb Bio Inc (NASDAQ:CLYM) trade information
Instantly CLYM has showed a red trend with a performance of -2.99% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.0700 on recent trading dayincreased the stock’s daily price by 5.8%. The company’s shares are currently up 8.33% year-to-date, but still down -2.50% over the last five days. On the other hand, Climb Bio Inc (NASDAQ:CLYM) is -19.42% down in the 30-day period. We can see from the shorts that 4.82 million shares have been sold at a short interest cover period of 13.74 day(s).
Climb Bio Inc (CLYM) estimates and forecasts
Climb Bio Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -71.20 percent over the past six months and at a -20.77% annual growth rate that is well below the industry average of 16.50%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -46.72%.
CLYM Dividends
Climb Bio Inc’s next quarterly earnings report is expected to be released in February.
